Advertisement

Cancer Immunology, Immunotherapy

, Volume 30, Issue 2, pp 119–125 | Cite as

THF-γ2, a thymic hormone, increases immunocompetence and survival in 5-fluorouracil-treated mice bearing MOPC-315 plasmacytoma

  • Rachel Ophir
  • Marit Pecht
  • Drora Halperin
  • Gloria Rashid
  • Yigal Burstein
  • Shlomo Ben-Efraim
  • Nathan Trainin
Original articles

Summary

The effect of the thymic hormone, THF-γ2, on the immunocompetence of 5-fluorouracil (5-FU)-treated BALB/c mice, bearing MOPC-315 tumor, was examined. Treatment of noninoculated or tumor-bearing mice with THF-γ2 after 5-FU injection, resulted in an increase in the antibody response to sheep red blood cells and in the allogeneic response in spleen cell cultures and had no effect on the concanavalin-A-induced interleukin-2 secretion beyond that caused by 5-FU alone. Treatment with either 5-FU alone or 5-FU and THF-γ2 resulted in restoration to normal values of Lytl- and L3T4-positive populations in tumor-bearing mice. THF-γ2 prolonged the survival time of mice bearing MOPC-315 tumor beyond that observed in mice treated with 5-FU alone.

Keywords

Cell Culture Blood Cell Cancer Research Survival Time Antibody Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ben-Efraim S, Bocian RC, Mokyr MB, Dray S (1983) Increase in effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol Immunother 15: 101Google Scholar
  2. 2.
    Ben-Efraim S, Shoval S, Ophir R (1986a) The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma. Cancer Immunol Immunother 22: 43Google Scholar
  3. 3.
    Ben-Efraim S, Shoval S, Gal T, Ophir R (1986b) Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity. Anticancer Res 6: 801Google Scholar
  4. 4.
    Bocian CB, Ben-Efraim S, Dray S, Mokyr MB (1984) Melphalan mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 18: 41Google Scholar
  5. 5.
    Burstein Y, Buchner V, Pecht M, Trainin N (1988) THF-γ2: purification and amino acid sequence of an immunoregulatory peptide from calf thymus. Biochemistry 27: 4066Google Scholar
  6. 6.
    Cunningham AJ, Szenberg A (1968) Further improvements in the plaque technique for detecting single antibody forming cells. Immunology 14: 599Google Scholar
  7. 7.
    David M, Shohat B, Trainin N, Feuerman E (1980) Cell mediated immunity in patients with mycosis fungoides in clinical remission. Effect of thymic humoral factor on the immunocompetence of the lymphocytes. Cancer 46: 41Google Scholar
  8. 8.
    David M, Shohat B, Feuerman E, Trainin N (1980) B and T lymphocytes in lymphoproliferative diseases of the skin. Effect of a thymic hormone on the immunocompetence of thymocytes. Br J Dermatol 102: 145Google Scholar
  9. 9.
    Eipert EF, Adorini L, Couderc J (1978) A miniaturized in vitro diffusion culture system. J Immunol Methods 22: 283Google Scholar
  10. 10.
    Gillis S, Ferm MW, Ou W, Smith KA (1978) T-cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027Google Scholar
  11. 11.
    Globerson A, Rotter V, Nakamura I, Trainin N (1973) Thymus extracts induced differentation of thymus derived cells. In: Jankovic BD, Isakovic K (eds) Microenvironmental aspects of immunity. Plenum Publishing Co. N.Y., p 183Google Scholar
  12. 12.
    Hengst JCD, Mokyr MB, Dray S (1980) Importance of timing in cyclophosphamide therapy of MOPC-315 tumor bearing mice. Cancer Res 40: 2135Google Scholar
  13. 13.
    Hengst JCD, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41: 2163Google Scholar
  14. 14.
    Julius MH, Simpson E, Herzenberg LA (1973) A rapid method for the isolation of functional thymus derived murine lymphocytes. Eur J Immunol 3: 645Google Scholar
  15. 15.
    Kook AI, Yakir Y, Trainin N (1975) Isolation and partial chemical characterization of THF, a thymic hormone, involved in immune maturation of lymphoid cells. Cell Immunol 19: 151Google Scholar
  16. 16.
    Levey RH, Trainin N, Law LW (1963) Evidence for function of thymus tissue in diffusion chambers implanted in neonatally thymectomized mice. J Natl Cancer Inst 31: 199Google Scholar
  17. 17.
    Merrifield RB (1963) The solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85: 2149Google Scholar
  18. 18.
    Mokyr MB, Colvin M, Dray S (1985) Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Int J Immunopharmacol 7: 111Google Scholar
  19. 19.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55Google Scholar
  20. 20.
    Osawa M, Diamanstein T (1984) A rat monoclonal antibody that binds specifically the mouse T lymphoblasts and inhibits IL-2 receptor functions: a putative anti-IL-2 receptor antibody. J Immunol 132: 2445Google Scholar
  21. 21.
    Rotter V, Globerson A. Nakamura I, Trainin N (1973) Studies on characterization of the lymphoid target cell for activity of a thymus humoral factor. J Exp Med 138: 130Google Scholar
  22. 22.
    Rotter V, Trainin N (1977) Effect of thymic hormone on the response of different lymphoid cell populations to T-mitogens. Isr J Med Sci 13: 363Google Scholar
  23. 23.
    Smith KA, Cantrell (1985) A Interleukin 2 regulates its own receptors. Proc Natl Acad Sci USA 32: 864Google Scholar
  24. 24.
    Trainin N, Small M, Globerson A (1969) Immunocompetence of spleen cells from neonatally thymectomized mice conferred in vitro by a syngeneic thymus extract. J Exp Med 130: 765Google Scholar
  25. 25.
    Trainin N, Kook AI, Umiel T, Albala M (1975) The nature and mechanism of stimulation of immune responsiveness by thymus extracts. Ann NY Acad Sci 249: 349Google Scholar
  26. 26.
    Trainin N, Zaizov R, Pecht M, Shohat B, Yakir Y (1980) The role of THF in immune modulation in patients receiving antineoplastic chemotherapy. In: Serrou B, Rosenfeld C (eds) International symposium on new trends in human immunology and cancer immunotherapy. Doin Editeurs, Paris, p 727Google Scholar
  27. 27.
    Trainin N, Handzel ZT, Pecht M (1985) Biological and clinical properties of THF. Thymus 7: 137Google Scholar
  28. 28.
    Trainin N, Burstein Y, Ben Efraim S, Goebel FD and Handzel ZT (1986) The use of the THF, a thymic hormone, for immunomodulation in cancer and AIDS. In: Novel approaches in cancer therapy. Lectures and Symposia 14th Int. Cancer Congr. Lapis/Eckhardt (eds) Budapest Vol. 5, p 253Google Scholar
  29. 29.
    Umiel T, Trainin N (1975) Increased reactivity of responding cells in the mixed lymphocyte reaction by a thymic humoral factor. Eur J Immunol 5: 85Google Scholar
  30. 30.
    Zaizov R, Vogel R, Wolach B, Cohen IJ, Varsano I, Shohat B, Handzel ZT, Rotter V, Yakir Y, Trainin N (1979) The effect of THF in lymphoproliferative and myeloproliferative diseases in children. Ann NY Acad Sci 332: 172Google Scholar
  31. 31.
    Zaizov R, Vogel R, Cohen IJ, Dvir A, Shohat B, Umiel T, Pecht M, Trainin N (1980) The immunomodulatory effect of THF in children with acute myelogenous leukemia. In: Serrou B, Rosenfeld C (eds) International symposium on new trends in human immunology and cancer immunotherapy. Doin Editeurs, Paris, p 807Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Rachel Ophir
    • 1
  • Marit Pecht
    • 2
  • Drora Halperin
    • 1
  • Gloria Rashid
    • 1
  • Yigal Burstein
    • 3
  • Shlomo Ben-Efraim
    • 1
  • Nathan Trainin
    • 2
  1. 1.Department of Human Microbiology, Sackler School of MedicineTel Aviv UniversityTel-AvivIsrael
  2. 2.Department of Cell BiologyThe Weizmann Institute of ScienceRehovotIsrael
  3. 3.Department of Organic ChemistryThe Weizmann Institute of ScienceRehovotIsrael

Personalised recommendations